EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of the Her-2/neu value in papillary thyroid carcinoma and its relation to histopathological prognostic findings

Amin Azarnoosh, Elahe Farmani, Farzaneh Niki Boroujeni, Elham Nazar

Cancer Treatment and Research Communications · 2024

DOI: 10.1016/j.ctarc.2024.100840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2024. Verfasst von Amin Azarnoosh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Sina Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tehran University of Medical Sciences and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Thyroid cancer is an important endocrine malignancy worldwide, including papillary carcinoma, which is responsible for more than 90 % of thyroid malignancies. Human epidermal growth factor receptor 2 (Her-2/neu) overexpression plays a significant act in the development, progression, and invasion of various tumors through effects on the cell cycle, angiogenesis, cell movement, and apoptosis. OBJECTIVE AND METHODS: The study was conducted as a cross-sectional study, using tissue samples from 53 patients who underwent lobectomy or total thyroidectomy between 2020 and 2022. For histopathological examination and to determine the pathological features of the tumor, tumor specimens were stained for immunohistochemistry using a monoclonal antibody against Her-2/neu. RESULTS: In this study, Her-2/neu was expressed in 13.2 % of PTC patients and not expressed in normal thyroid tissue. No significant relationship was established between Her-2/neu expression and tumor histological subtype, as well as tumor size, sex, or tumor focality. Furthermore, there was no significant association between Her-2/neu expression and vascular invasion or extrathyroidal extension of the tumor. CONCLUSION: No significant Her-2/neu expression was observed in the malignant thyroid tissue. These findings raise questions about the value of Her-2/neu as a potential prognostic factor or target of a specific anticancer treatment for thyroid cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesThyroid Cancer, PapillaryThyroid NeoplasmsHumansFemaleMalePrognosisMiddle AgedCross-Sectional StudiesAdultAgedBiomarkers, TumorThyroidectomyImmunohistochemistry

Stichwörter der Autor:innen

Her-2/neuPapillary thyroid carcinomaPrognosisThyroid cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Sina Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Pathology, Sina Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: enazar@tums.ac.ir.

Förderung

  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Azarnoosh, A., Farmani, E., Niki Boroujeni, F., & Nazar, E. (2024). Evaluation of the Her-2/neu value in papillary thyroid carcinoma and its relation to histopathological prognostic findings. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2024.100840

Vancouver

Azarnoosh A, Farmani E, Niki Boroujeni F, Nazar E. Evaluation of the Her-2/neu value in papillary thyroid carcinoma and its relation to histopathological prognostic findings. Cancer Treatment and Research Communications. 2024. doi:10.1016/j.ctarc.2024.100840

BibTeX
@article{Azarnoosh2024,
  author = {Azarnoosh, Amin and Farmani, Elahe and Niki Boroujeni, Farzaneh and Nazar, Elham},
  title = {Evaluation of the Her-2/neu value in papillary thyroid carcinoma and its relation to histopathological prognostic findings},
  journal = {Cancer Treatment and Research Communications},
  year = {2024},
  doi = {10.1016/j.ctarc.2024.100840}
}
Kostenlos starten →